He was most recently executive vice president, head of global product development, and chief medical officer of Hoffmann-La Roche. There he was responsible for all the products in the combined portfolio of Roche and Genentech. Barron joined Genentech in 1996 as a clinical scientist. During the next several years, he held positions of increasing responsibility and leadership within cardiovascular research and specialty therapeutics. In 2002 Barron was promoted to vice president of medical affairs. In 2003 he became the senior vice president of development. In 2004 he was appointed chief medical officer and in 2009 he was appointed executive vice president.
Prior to joining Genentech, Barron received his Bachelor of Science in physics from Washington University in St. Louis, his medical degree from Yale University, and completed his training in medicine and cardiology at the University of California San Francisco. Barron’s academic positions include associate adjunct professor at the University of California, San Francisco. He has been issued several patents for his work in thrombosis and angiogenesis and has published more than 90 papers in peer-reviewed scientific journals.